ArticleDEN open2025
Feasibility of a novel self-assembling submucosal injection peptide solution for endoscopic mucosal resection of colorectal lesions: A multicenter study.
Article in DEN open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of topical self-assembling peptide in preventing delayed bleeding following advanced endoscopic resection: a systematic review and meta-analysis.Surgical endoscopy · 2026Pooled it
- SAFETY AND EFFECTIVENESS OF BLUE EYE HYPERTONIC SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF FLAT COLONIC LESIONS: A RANDOMIZED CLINICAL TRIAL.Arquivos de gastroenterologia · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Although a novel submucosal injection material consisting of a fully synthetic, self-assembling peptide solution, PuraLift, has recently become commercially available in Japan, there are a few reports regarding the usefulness of this solution. The aim of this study was to investigate the feasibility of PuraLift for conventional endoscopic mucosal resection (EMR) in clinical practice. Methods: This multicenter retrospective study was conducted at the endoscopy units of five institutions from January 2023 to May 2023. Consecutive patients who underwent EMR with PuraLift for 5-20-mm colorectal lesions were included in the introduction of this solution at each institute. The primary endpoint was the "effective resection" rate, defined as pathological complete resection, with "effective injection" defined as requiring no more than one additional injection due to adequate maintenance of mucosal lifting during EMR. Results: In total, 110 lesions in 70 patients were treated by conventional EMR using PuraLift. En-bloc resection was performed for 109 (99%) lesions, and complete resection was performed for 102 (93%) lesions. More than 95% of the lesions were neoplastic. Additional injections were required in only two lesions. Both were single additional injections, and the median overall injection volume was 1.5 mL. Therefore, the effective injection rate was 93% (95% confidence interval, 86%-96%). No adverse events occurred during the study period. Conclusions: Although direct comparison with other materials is required, PuraLift seems feasible as an injection material for EMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.